Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

[PSA progression under hormone therapy - of prognostic relevance?].

Miller K.

Aktuelle Urol. 2012 Jul;43(4):262-4. doi: 10.1055/s-0032-1321735. Review. German.

PMID:
22869497
2.

Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.

Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN.

Urol Int. 2005;75(3):217-21.

PMID:
16215308
3.

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH.

J Natl Cancer Inst. 2004 Apr 7;96(7):509-15.

PMID:
15069112
4.

Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.

Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, Shimazaki J.

Jpn J Clin Oncol. 2008 Jan;38(1):36-42. doi: 10.1093/jjco/hym153.

PMID:
18258713
5.

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.

Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M; Chiba Prostate Study Group..

Urology. 2004 Aug;64(2):341-5.

PMID:
15302491
6.
7.

Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).

Collette L, de Reijke TM, Schröder FH; EORTC Genito-Urinary Group..

Eur Urol. 2003 Aug;44(2):182-9; discussion 189.

PMID:
12875936
8.

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.

Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH; European Organisation for Research and Treatment of Cancer.; Limburgs Universitair Centrum.; AstraZeneca Pharmaceuticals..

J Clin Oncol. 2005 Sep 1;23(25):6139-48.

PMID:
16135480
10.
11.

Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.

Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K, Takimoto Y.

Urol Int. 2005;75(1):43-9.

PMID:
16037707
13.

Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.

Kwak C, Jeong SJ, Park MS, Lee E, Lee SE.

J Urol. 2002 Sep;168(3):995-1000.

PMID:
12187207
14.

Cytokine variations in patients with hormone treated prostate cancer.

Wise GJ, Marella VK, Talluri G, Shirazian D.

J Urol. 2000 Sep;164(3 Pt 1):722-5.

PMID:
10953133
15.

Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.

Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV.

Cancer. 2006 Jan 1;106(1):63-7.

16.

Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer.

Zhang M, Mahta A, Kim RY, Akar S, Kesari S.

Med Oncol. 2012 Jun;29(2):806-8. doi: 10.1007/s12032-011-9906-z.

PMID:
21424585
17.

[Current strategies of intermittent hormone therapy in prostate cancer].

Kaprin AD, Pavlov AIu, Ivanov SA, Gafanov RA.

Vopr Onkol. 2011;57(2):260-4. Russian.

PMID:
21809677
19.

Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?

Ward JF.

Nat Clin Pract Urol. 2006 Jun;3(6):310-1. No abstract available.

PMID:
16763642
20.

Should we follow-up serum testosterone in patients with advanced prostate cancer?

Perachino M.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1031-5. doi: 10.1586/era.10.92. Review.

PMID:
20645692

Supplemental Content

Support Center